Technical Analysis for AFMD - Affimed Therapeutics B.V.

Grade Last Price % Change Price Change
grade D 3.54 -0.28% -0.01
AFMD closed down 0.28 percent on Friday, January 18, 2019, on 23 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical AFMD trend table...

Date Alert Name Type % Chg
Jan 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 18 Inside Day Range Contraction 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.28%
Jan 17 Inside Day Range Contraction -0.28%
Jan 17 Wide Bands Range Expansion -0.28%
Jan 16 Wide Bands Range Expansion -1.39%
Jan 14 Narrow Range Bar Range Contraction 4.12%
Jan 14 NR7 Range Contraction 4.12%
Jan 14 Down 3 Days in a Row Weakness 4.12%

Older signals for AFMD ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company's product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Is AFMD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.35
52 Week Low 1.3
Average Volume 738,879
200-Day Moving Average 2.9295
50-Day Moving Average 3.7316
20-Day Moving Average 3.2795
10-Day Moving Average 3.512
Average True Range 0.2457
ADX 20.41
+DI 25.5298
-DI 14.3725
Chandelier Exit (Long, 3 ATRs ) 3.1029
Chandelier Exit (Short, 3 ATRs ) 3.5271
Upper Bollinger Band 3.7938
Lower Bollinger Band 2.7652
Percent B (%b) 0.75
BandWidth 31.364537
MACD Line -0.011
MACD Signal Line -0.0704
MACD Histogram 0.0594
Fundamentals Value
Market Cap 155.54 Million
Num Shares 43.9 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -3.56
Price-to-Sales 22.02
Price-to-Book 1.82
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.75
Resistance 3 (R3) 3.75 3.67 3.72
Resistance 2 (R2) 3.67 3.62 3.68 3.70
Resistance 1 (R1) 3.61 3.59 3.57 3.61 3.69
Pivot Point 3.53 3.53 3.52 3.54 3.53
Support 1 (S1) 3.47 3.48 3.43 3.47 3.39
Support 2 (S2) 3.39 3.45 3.40 3.38
Support 3 (S3) 3.33 3.39 3.37
Support 4 (S4) 3.33